ELQ-331 as a prototype for extremely durable chemoprotection against malaria.
Martin J SmilksteinSovitj PouAlina KrollenbrockLisa A BleyleRozalia A DodeanLisa FruehDavid J HinrichsYuexin LiThomas MartinsonMyrna Y MunarRolf W WinterIgor BruzualSamantha WhitesideAaron NilsenDennis R KoopJane X KellyStefan H I KappeBrandon K WilderMichael K RiscoePublished in: Malaria journal (2019)
Extrapolation of these results to humans predicts that ELQ-331 should be capable of meeting and far-exceeding currently published duration-of-effect goals for anti-malarial LAI-C. Furthermore, the distinctive pharmacokinetic profile of ELQ-300 after treatment with ELQ-331 may facilitate durable protection and enable protection for far longer than 3 months. These findings suggest that ELQ-331 warrants consideration as a leading prototype for LAI-C.